title: Retinal function after subconjunctival injection of carboplatin in fibrin sealant.
abstract: OBJECTIVE
  To evaluate retinal function in a rabbit model after subconjunctival delivery of carboplatin in balanced saline solution (BSS) or fibrin sealant to determine possible retinal toxicity.
  
  
  METHODS
  One group of rabbits (n = 5) received a unilateral subconjunctival injection of 12.2 +/- 1.0 mg/mL of carboplatin (Paraplatin) in BSS. Another group of rabbits (n = 5) received 25.1 +/- 7.7 mg/mL of carboplatin in fibrin sealant (Hemaseel APR). Rabbits injected with fibrin sealant only (n = 2) and BSS only (n = 2) were used as control groups. Electroretinographic recordings consisted of a series of intensities presented under dark- and light-adapted conditions. Electroretinograms were recorded before the injection (baseline) and 2 days, 1, 2, and 3 weeks after the injection. After 3 weeks, all rabbit eyes were obtained for histopathologic examination.
  
  
  RESULTS
  Transient reductions in the dark-adapted b-wave amplitudes were noted 2 days after treatment for eyes injected with carboplatin compared with the vehicle-only treatment groups. Other treatment groups and postinjection time points showed no significant changes from baseline. Retinal structure and thickness were normal 3 weeks after treatment for all treatment groups.
  
  
  CONCLUSIONS
  Subconjunctival delivery of carboplatin in fibrin sealant or BSS does not have a toxic effect on retinal function or structure in a non-tumor-bearing rabbit model at the doses used in this study at 3 weeks' follow-up.
authors.affiliation: Department of Ophthalmology, Emory University, Atlanta, Georgia, USA.
authors.forename: Machelle T
authors.initials: MT
authors.lastname: Pardue
authors.forename: Charles
authors.initials: C
authors.lastname: Hejny
authors.forename: Jake A
authors.initials: JA
authors.lastname: Gilbert
authors.forename: M Joe
authors.initials: MJ
authors.lastname: Phillips
authors.forename: Dayle H
authors.initials: DH
authors.lastname: Geroski
authors.forename: Henry F
authors.initials: HF
authors.lastname: Edelhauser
mesh_terms: D000085:Acetates; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D016190:Carboplatin / Q000008:administration & dosage / Q000633:toxicity*; D003228:Conjunctiva; D003623:Dark Adaptation; D004337:Drug Carriers; D004338:Drug Combinations; D004596:Electroretinography / Q000187:drug effects; D015718:Fibrin Tissue Adhesive / Q000008:administration & dosage / Q000633:toxicity*; D007267:Injections; D008903:Minerals; D011817:Rabbits; D012160:Retina / Q000187:drug effects* / Q000502:physiology*; D012965:Sodium Chloride; D014014:Tissue Adhesives / Q000008:administration & dosage / Q000633:toxicity*
chemical_list: D000085:Acetates; D000970:Antineoplastic Agents; C030660:BSS solution; D004337:Drug Carriers; D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive; D008903:Minerals; D014014:Tissue Adhesives; D012965:Sodium Chloride; D016190:Carboplatin